Vallet-Pichard Anaïs, Parlati Lucia, Pol Stanislas
Hôpital Cochin, département d'hépatologie, 27, rue du Fg-Saint-Jacques, 75014 ParisFrance.
Hôpital Cochin, département d'hépatologie, 27, rue du Fg-Saint-Jacques, 75014 ParisFrance; AP-HP, université Paris Descartes, 15, rue de l'École de Médecine, 75006 Paris, France.
Presse Med. 2019 Dec;48(12):1459-1467. doi: 10.1016/j.lpm.2019.08.008. Epub 2019 Nov 19.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease, the most common cause of chronic liver function augmentation and it will be the most common indication for liver transplantation in 2020. The prevalence of NAFLD has increased over time in line with the increase of obesity and type 2 diabetes. There is a discrepancy between the studies concerning the prevalence of NAFLD because of the different diagnostic methods used (ultrasound or magnetic resonance, fibroscan, controlled attenuation parameter (CAP), histology). Because of its high prevalence the impact of NAFLD in public health is real. Therapeutic advances must be made to better understand the natural history of NAFLD and improve the management of this emerging liver disease.
非酒精性脂肪性肝病(NAFLD)是肝病最常见的病因,是慢性肝功能增强最常见的病因,并且将成为2020年肝移植最常见的指征。随着肥胖症和2型糖尿病的增加,NAFLD的患病率随时间推移而上升。由于所使用的诊断方法不同(超声或磁共振、FibroScan、受控衰减参数(CAP)、组织学),关于NAFLD患病率的研究存在差异。由于其高患病率,NAFLD对公共卫生的影响是切实存在的。必须取得治疗进展,以更好地了解NAFLD的自然病史,并改善对这种新兴肝病的管理。